Our Vice President of North American Business Development, Daniel Conlon, will be at the Boston…
We were delighted to author a recent Bioanalysis Zone article discussing the power of high-resolution mass spectrometry (HRMS) when investigating peptide-based modalities in drug discovery. In the article, Simone Esposito, Research Investigator in the DMPK group, explores the extensive applications of the technology for understanding the intricate drug metabolism and pharmacokinetics of complex peptide drugs.
The article highlights how peptide-based drugs have emerged as a solution for reaching targets previously thought to be undruggable. It then discusses how IRBM uses HRMS to comprehensively analyse complex modalities including cyclic peptides and peptide conjugates, delivering confidence in customers’ drug candidates.
Read the article here: [Link to article]